⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
globenewswire.com
AMRX
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
prnewswire.com
AMRX
APLS
FITB
HBAN
LZ
PCH
TTMI
AHR
BROS
CADE
CIVI
CMA
ELME
RYN
SM
SPGI
AEIS
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
globenewswire.com
AMRX
Sodium Chloride Injections Market, Global Forecast 2026-2032 - Clinical Practice Migration and Manufacturing Modernization are Driving Innovations
globenewswire.com
AMRX
ICUI
PFE
Buprenorphine Patches Market Forecast Intelligence Report 2026-2032: Global, Regional and Country-Level Coverage
globenewswire.com
AMRX
VRTS
TEVA
LPCN
SUN
Topiramate Drugs Market - Global and Regional Trends, Drivers, and Growth Forecast 2026-2032 with Competition and Value Chain Analysis
globenewswire.com
AMRX
JNJ
TEVA
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
businesswire.com
AMRX
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
globenewswire.com
AMRX
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease
businesswire.com
AMRX
Zambon Biotech annonce la première administration d'IPX203 à un patient dans le cadre de l'étude clinique ADIP de phase 3b dans la maladie de Parkinson
businesswire.com
AMRX